- Cannabis Edibles Are Triggering Poisonings Among Older Users
- A Matcha Mouthwash Might Fight Gum Disease
- ‘Hungry Gut’ Gene Test Shows Who’ll Benefit Most From Wegovy
- For Pregnant Women, Fluoridated Drinking Water Might Raise Risks for Baby: Study
- Vaping After Quitting Smoking Keeps Lung Cancer Risk High
- To Boost Colon Cancer Screening, Give Patients Choices
- Quit-Smoking Drug Chantix May Also Help Folks Stop Vaping
- More Kids With Asthma Need Hospital Care on Very Hot Days
- Deadly GallBladder Cancers Rising Among Black Americans
- Repeat COVID Vaccination Could Shield Against Wide Range of Viruses
New Hemophilia Remedy Offers Potential for Fewer Injections
Eloctate, Antihemophilic Factor Fc Fusion has been approved by the U.S. Food and Drug Administration for people with Hemophilia A. It’s designed to require less frequent injections than standard therapies used to reduce the frequency of bleeding episodes in people with the disorder, the FDA said in a news release.
Hemophilia A is an inherited bleeding disorder that affects mostly males. Caused by a defective Factor VIII gene, it affects about 1 in 5,000 males in the United States. People with the disorder are prone to serious bleeding episodes, primarily affecting the joints.
Eloctate’s safety and effectiveness were evaluated in a clinical study of 164 people. No safety concerns were identified in the trial, the FDA said.
The product is produced by Biogen Idec, based in Cambridge, Mass.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.